CIAM
SPRO icon

Caitong International Asset Management’s Spero Therapeutics SPRO Stock Holding History

Caitong International Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$7 – 3427
2026
Q1 		$7 Buy
+3
New +$7 ﹤0.01% 2210

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caitong International Asset Management's SPRO Position: Q2 2026 in Review

Caitong International Asset Management sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 3 shares — an estimated $7 sold.

Caitong International Asset Management first reported a position in SPRO in Q1 2026 and held it in 1 quarter. The position peaked at $7 in Q1 2026. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Caitong International Asset Management reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 3 Spero Therapeutics shares in Q2 2026, an estimated $7.
  • Caitong International Asset Management first reported a position in Spero Therapeutics in Q1 2026 and held it in 1 quarter.
  • Caitong International Asset Management's Spero Therapeutics position peaked at $7 in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.